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The efficacy of an early and low inoculum-adjusted marbofloxacin treatment was
evaluated on microbiological and clinical outcomes in calves infected with 4.107 CFU
of Mannheimia haemolytica A1. Twenty-two calves were included based on their rectal
temperature rise in the 10 h after challenge and allocated in four groups, receiving a single
intramuscular injection of saline (CON), 2mg/kg marbofloxacin 2–4 h after inclusion (early
treatment, E2), 2 or 10mg/kg marbofloxacin 35–39 h after inclusion (late treatments, L2,
L10). In CON calves,M. haemolytica DNA loads in bronchoalveolar lavages continuously
increased from inclusion to day 4, and were associated with persistent respiratory clinical
signs and lung lesions. At times of early and late treatments,M. haemolytica loads ranged
within 3.5–4 and 5.5–6 log10 DNA copies/mL, respectively. Early 2mg/kg marbofloxacin
treatment led to rapid and total elimination of bacteria in all calves. The late treatments
induced a reduction of bacterial loads, but 3 of 6 L2 and 1 of 6 L10 calves were
still positive for M. haemolytica at day 4. Except for CON calves, all animals exhibited
clinical improvement within 24 h after treatment. However, early 2mg/kg treatment was
more efficacious to prevent pulmonary lesions, as indicated by the reduction of the
extension and severity of gross lesions and by the histopathological scores. These results
demonstrated for the first time that a reduced antibiotic regimen given at an early stage
of the disease and targeting a low bacterial load could be efficacious in a natural bovine
model of pneumonia.
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INTRODUCTION
Bovine respiratory disease (BRD) is a major economic concern
in young beef cattle production, with a huge economic
impact on the farming industry due to production losses and
disease treatment and prevention (United State Department of
Agriculture, 2013). BRD is mostly multifactorial due to complex
interactions between pathogens (virus and/or bacteria and/or
fungi), animal (host) factors and non-infectious environmental
variables, such as farm management determinants (Fulton,
2009). Among the Gram-negative bacteria, the virulence factors
expressed byMannheimia haemolytica, such as leukotoxin, make
it the major bacterial agent of BRD, resulting in high mortality,
and loss of productivity in young calves (Van Donkersgoed
et al., 1993; Zecchinon et al., 2005). At the herd level, the
disease prevalence in suckler calves or young bull production is
estimated to be∼15%, with high variability within herds (Cusack
et al., 2003; Assie et al., 2009; Pardon et al., 2011). Recently, M.
haemolytica was detected by real-time PCR in France in∼20% of
respiratory samples from BRD (Pelletier, 2013).
Because of the high prevalence of Gram-negative bacteria as
involved pathogens, the frequent association between bacteria
and viruses, and the absence of pathogen identification in
field conditions, the control of BRD generally includes the use
of Gram-negative spectrum antibiotics (Apley, 1997; Fulton,
2009). Two therapeutic strategies are commonly implemented
by veterinarians and farmers. Metaphylaxis represents a current
practice of early BRD treatment, that consists in treating the
entire cohort of animals, in which only a few express clinical
signs of BRD (Nickell and White, 2010; Forbes et al., 2011).
The advantages of this approach are good survival rate in the
cohort and ease of use (Nickell and White, 2010); it also has
the disadvantage of exposing to antibiotics a potentially large
proportion of animals intended for human consumption even
when not required. A second therapeutic approach consists in
treating only the affected animals, regardless of the severity of
their clinical signs (O’Connor et al., 2013; Heins et al., 2014).
This approach limits exposure to antibiotics and decreases the
risk of developing resistant strains. However, it is usually seen
as the “late approach” because the clinical signs and possibly
extensive pulmonary damage have had time to develop prior to
treatment, as demonstrated for Pasteurellaceae (Ackermann and
Brogden, 2000; Dagleish et al., 2010). Fluoroquinolones, such as
marbofloxacin, represent a frequent “late approach” treatment for
BRD in Europe. Considering the uncertainty regarding the causal
agent and time of disease onset, labeled doses are determined
by pharmacokinetics (PK) and pharmacodynamics (PD) and
dose determination experiments. These doses generally target a
cluster of pathogens and consider the highest minimal inhibiting
concentration (MIC) reported (Toutain et al., 2002; Valle et al.,
2012). These conditions also lead to routine use of a “high”
antibiotic dose.
Antimicrobial usage leads to unavoidable selection of
resistance in pathogens and commensal bacteria (Courvalin,
2005, 2008). Previous evidence has demonstrated the transfer of
resistant bacteria or genetic determinants of resistance between
animals and humans (Aarestrup and Wegener, 1999; Angulo
et al., 2004; Bywater, 2004). Therefore, a wide consensus in
both human and veterinary medicine encourages the reduction
of antimicrobial usage to reduce its potential impact on public
health. In parallel recent studies have stressed the interests of
early therapeutic interventions, when the infectious bacterial load
is low, suggesting that the dose of antibiotics may be modulated
concurrently with the infectious bacterial load in both human
and veterinary medicine (Ferran et al., 2007, 2011; Martinez
et al., 2012; Vasseur et al., 2014). For example, in an experimental
mouse-lung infection model with Pasteurella multocida, a lower
dosage of fluoroquinolone was required to achieve similar
bacteriological outcomes when administered “early” compared
with a late administration pattern (Ferran et al., 2011). Further, an
in vitro study observed high bactericidal activity ofmarbofloxacin
even at low concentrations on low inoculum of both M.
haemolytica and P. multocida (Illambas et al., 2013). Up to now,
such observations have not been reported in a natural host model.
These findings open new perspectives regarding the rational
use of antibiotics in farm animals, combining the objectives of
reducing their consumption and preserving animal health. In this
context, this study aimed to determine the impact of an early
and decreased regimen of marbofloxacin on the bacteriological
burden, the extent of pulmonary lesions and the clinical recovery
in calves experimentally infected withM. haemolytica A1.
MATERIALS AND METHODS
Bacteria and Culture
M. haemolytica A1 strain 11-01-840 was isolated from the lungs
of a calf with clinical signs of BRD in 2010 and stored at −80◦C.
Prior to each use, one aliquot of the strain was defrosted,
and cultured on a Mueller Hinton Agar plate. The MIC was
determined inMueller Hinton Broth in triplicate according to the
CLSI referencemethods (CLSI, 2009). TheMIC of marbofloxacin
was 0.03µg/mL.
M. haemolytica A1 strain 11-01-840 inoculum was prepared
as follows: at day-1 (D-1) prior to inoculation, the strain was
incubated overnight in 500mL of brain heart infusion broth
(BHIB) at 37◦C; at day 0 (D0) just prior to inoculation, 50mL of
BHIB was centrifuged at 3000 g for 20min; pellets were collected
in 10mL of 0.9% NaCl and washed twice in the same buffer; and
the final pellet was then diluted into pre-warmed 0.9% NaCl to
obtain a final suspension containing 2.105 CFU/mL. Each calf
was inoculated with 200mL of the final suspension.
Experimental Infection of Calves with M.
haemolytica
Animal experimentation was performed as prescribed by the
guidelines of the European Community Council on Animal
Care (2010/63/EU), in accordance with accepted human
standards of animal care, under ethical agreement number
TOXCOM/0021/AF GL (French Ministry of Agriculture, Ethics
Committee -C2EA-86).
Thirty-two dairy Holstein and Normand calves were selected
at birth and reared until to 2–3 weeks of age (weight ranged
from 47 to 75 kg) in French experimental units with no
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history of BRD (INRA, Domaine de Borculo, Exmes, France).
Calves were colostrum-deprived after birth and fed with an
oral rehydration solution the first 2 days to avoid transfer
of immunoglobulins against bovine respiratory syncytial virus
(BRSV), bovine parainfluenza virus type (BPI3) as well as
M. haemolytica. Then they were fed until day 7 of age
with milk replacer and a colostrum substitute (negative for
BRSV/BPI3 antibodies), as previously described (Riffault et al.,
2010). Calves were transported at 2–3 weeks of age and
allocated to specific experimental units in collective pens of
three to four animals with free access to hay and fresh water
(experimental units of Toulouse, France). They were fed ad
libitum with starter food (Passio Floc Junior, SudOuestAliments,
Anan, France) and once a day with a milk replacer (Laitine
Tech R©, Bonilait-protéines, Chasseuneuil du Poitou, France).
Upon arrival at the experimental unit, calves received a
single intramuscularly injection of E-vitamin and selenium
(0.025mg/kg, Selephérol R©, Vetoquinol, France) and underwent
a complete physical examination. They remained fully healthy
during the 8-day period prior to challenge. Absence of bovine
viral diarrhea virus (BVDV) in calves was assessed at birth by
negative real-time RT-PCR (Taqvet-BVDV kit, Lifetechnologie).
Absence of BRSV and BPI3 was subsequently confirmed
by negative serology of calves (LsiVet bovine RSV serum,
Life technologies) and negative quantitative RT-PCR (Taqvet
BRSV-bPI3 kit, Life technologies) on bronchoalveolar lavages
(BAL) at D0 just prior to challenge with M. haemolytica.
Absence ofM. haemolytica asymptomatic carriers was confirmed
by negative qPCR (TaqVet™ Triplex P. multocida and M.
haemolytica, Life technologies, USA) in nasal swabs 2 days prior
to inoculation.
Challenge was performed in calves between 3.5 and 5.5
weeks of age by intratracheal route as previously described
(Riffault et al., 2010). Briefly, calves were restrained (standing
up); an area of 20 cm2 was shaved at the median part of
the neckline. Then, a 18 G catheter (Intraflon G18, Vycon)
was inserted between two tracheal rings ∼10 cm below the
larynx. After location verification, 200ml of pre-warmed solution
containing 2.105 CFU/mL M. haemolytica was injected into
the catheter, corresponding to a total of 4.107 CFU per calf.
Calves were allocated into four groups based on elevation of
rectal temperatures after challenge. The basal temperature of
each calf was calculated as the mean rectal temperature collected
individually twice daily for the 3 days prior to challenge. After
challenge, rectal temperatures were taken every 3 h for a period
of 10 h.
During this 10-h period, 22 of 32 calves were included at time
0 (T0); their rectal temperature exceeded +1◦C their previously
basal temperature. Calves were randomly allocated to one of four
groups. The control group (4 CON calves) received no antibiotic
treatment; the E2 group (6 E2 calves) received an early single
intramuscular injection in the neck of 2mg/kg marbofloxacin
(Forcyl R©, Vetoquinol, Lure, France) at T1, 0–4 h after inclusion
(T0). The L2 and L10 groups (6 L2 and L10 calves per group)
were treated later at T2, at 35–39 h post-inclusion T0 (33–35 h
later than the early treatment), with a single injection of 2mg/kg
or 10mg/kg marbofloxacin, respectively.
To summarize, E2 calves (early treatment) were treated
between 0 and 4 h and L2 and L10 calves (late treatment) between
35 and 39 h post-inclusion, corresponding to 6–10 and 43–48 h
after M. haemolytica inoculation. Ten calves were excluded
because they failed to develop hyperthermia (mean+1◦C) in the
10-h period after inoculation of M. haemolytica. A description
of the experimental design, chronology of sampling and clinical
follow-up is presented in Figure 1.
The experiment ended 6 days after challenge, between 110
and 134 h post-challenge (time T3). Calves were euthanized
during experimentation for ethical reasons or at T3 under general
anesthesia overdose (5mg/kg ketamine, followed by 15mg/kg
pentobarbital sodium and exsanguination).
Clinical Examination and Respiratory
Sampling
Clinical observations were recorded twice a day from 3 days prior
to the end of experimentation, between 110 and 134 h (T3) post-
challenge. Rectal temperatures were measured every 3 h for a
period of 10 h after challenge, then twice daily, and at times of
inclusion (T0) and early (T1), and late (T2) treatments.
Calves were monitored using a scoring system adapted from
Dowling et al. (2002). Scores were assigned as follow: demeanor
from 0 to 3 (normal, dull, depressed, or recumbent); rectal
temperature from 0 to 2 (<39.5◦C, 39.5–40.5◦C, >40.5◦C);
respiratory rate from 0 to 3 (<45, 45–60, 60–90, >90); heart rate
from 0 to 2 (<80, 80–100, >100); nasal discharge from 0 to 3
(absent, mild, moderate, or profuse); intensity and added lung
sounds from 0 to 2 (normal, increased effort, or labored); and
appetite from 0 to 2 (normal, decreased, or anorexic). The clinical
score was calculated daily for each calf by adding the values
recorded for each parameter. In addition, individual accumulated
clinical scores (ACS) were calculated for each calf as the area
under daily clinical scores using the trapezoid method.
Bronchoalveolar lavages (BAL) were performed between 12
and 6 h prior to challenge for all 32 calves and at the end
of the experiment for the 22 included calves. In addition, for
three calves of each group (CON, E2, L2, and L10), BALs were
performed just prior to T1 and T2, the times of early and late
treatments, respectively. BALs on living animals were performed
under general anesthesia (10mg/kg ketamine and 10mg/kg
diazepam) by endoscopy (Olympus R©, CF-EL) as previously
described (Deplanche et al., 2007). For each BAL, a same volume
of 120mL of a sterile isotonic sodium chloride solution was
injected into the same location of the right lobe. The collected
volume varied between 65 and 80ml per calf and analyses were
carried out on 1mL for each BAL. Titers were expressed by
mL of BAL. BALs after euthanasia were performed by direct
extraction and lavages of the lungs as previously described
(Riffault et al., 2010). The recovered suspension was collected
and stored at −80◦C directly or after mixing with TRIzol R©
(Life Technologies, Saint Aubin, France) for quantitative M.
haemolytica PCR analysis.
Necropsy and Tissue Sampling
After euthanasia of the calves, gross lesions were photographed
and assessed by visual examination and palpation of each of the
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FIGURE 1 | Experimental timeline design of the study.
pulmonary lobes. Moreover, the percentage of cranioventral lung
consolidation was calculated as described by Amrine et al. (2014),
as cranial and ventral lobes are the most common lesion sites.
Post-mortem samples were collected for histopathology
and bacteriology, including cranial right and left, accessory,
cardiac, and caudal left and right lobes of the lungs, as well
as the mediastinal and tracheobronchial lymph nodes. For
histopathology, tissue samples were paraffin wax-embedded after
fixation in 10% neutral formalin, sectioned at 3–5µmand stained
with hemalun and eosin. A pathologist described and scored
the severity of histopathology and inflammation in each slide
as either normal (0), mild to moderate (1), or marked (2). A
mild to moderate score of 1 was defined by fibrinous alveolitis
with macrophagic infiltration, moderate quantities of mucus in
the lumen of bronchioles and occasional few, small abbesses.
A marked score of 2 was defined by hemorrhagic alveolitis
with major leucocyte infiltration, alteration of neutrophils,
foci of necrosis surrounded by oat cells, interlobular edema
and thrombosis, moderate quantities of mucus in the lumen
of bronchioles, and leucofibrinous pleuresia. A score of
histopathological severity was calculated for each calf as the sum
of all tissue slide-scores for that animal.
M. haemolytica Quantification
M. haemolytica quantification was performed by bacterial
titration on post-mortem samples and quantitative PCR on BAL
and post-mortem samples of included calves.
For titration, 1 g of the tissue sample collected from the right
cranial lobe of the lung was homogenized in 9mL of 0.9% NaCl.
The homogenates were centrifuged at 3000 g for 10min. The
supernatants were discarded, and the pellets were resuspended
in 10mL of 0.9% NaCl. Ten microliters of successive 10-fold
dilutions were then plated in triplicate on MH drug-free agar
plates for incubation at 37◦C. For all samples, bacterial counts
were recorded after 24 h of incubation, and the lowest level of
detection of colony counts was set at 100 CFU/g of tissue.
For quantitative PCR, DNA was extracted in elution buffer
from 200µL of BAL or 100mg of tissue samples using a
Macherey–Nagel nucleospin tissue genomic DNA kit. Five tissue
samples were collected at the same location for each calf,
including the right and left cranial, the accessory and the cardiac
lobes of the lungs and the tracheobronchial lymphatic node.
PCR was conducted with 5µL of elution buffer (50µL) with
the TaqVet™ Triplex P. multocida and M. haemolytica kit (Life
technologies, USA) according the manufacturer’s instructions
in a Light Cycler 480 (Roche). A standard plasmid curve for
quantification was obtained by successive 10-fold dilutions of a
plasmid containing 106 DNA copies of the same M. haemolytica
amplified nucleotide sequence (Life technologies, USA). In
addition, two housekeeping genes previously mentioned in the
literature (gapdh and rpl19) were amplified in each sample
to normalize the qPCR products using GeNorm software
(Biogazelle, qBase+). PCR results were analyzed using Roche
Light Cycler 480 software (release 1.5.1) using the standard
2nd derivative and fit points methods for all samples (Roche
Diagnostics). Results were similar when the PCR threshold
was defined by the software (2nd derivative method) or fixed
manually (fit points method) around 100 DNA copies. Results
are expressed as the mean of PCR titers for each group and
each day, after a logistic transformation, or as the accumulated
bacterial shed (ABS), which corresponds to the mean area under
individual curves of M. haemolytica detected by qPCR in BALs
from T0 to T3 (GraphPad Prism software analysis, La Jolla,
California, USA).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism
software (RRID: rid_000081, La Jolla, USA). For DNA
quantification statistical analyses were performed on
logarithmic-transformed data. A two-way ANOVA with
repeated measures was used for DNA quantification in BAL
and for clinical scores. The two-way ANOVA gave a p-value
<0.0001 for interaction between time/group (23.7 and 17.1%
of total variation respectively). Therefore, we considered that
the study had sufficient power for further analyses. As effects
of the “day” and “treatment” factors were significant among
interactions, Bonferroni adjustments for multiplicity were used
between contrasts to compare the treatments on each day. A
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two-way ANOVA without repeated measures was used for DNA
quantification in respiratory tissues. As the group effect was
significant (p < 0.001, 32.5% of total variation), Bonferroni
adjustments for multiplicity test were used to compare the group
effect for each tissue. A one-way ANOVA was used to compare
the histopathological score, ABS and ACS. As the effect of the
“treatment” factor was significant for ABS (p = 0.0059) and ACS
(p = 0.0168), a Newman–Keuls test was used to compare the
treatment effects between groups. No differences were observed
for histopathological score.
RESULTS
Early Treatment with the Low-Dose Led to
Rapid and Total Elimination of M.
haemolytica in BAL
The mean DNA loads of M. haemolytica in BAL over time
as well as the mean accumulated bacterial shedding (ABS)
scores are presented in Figure 2 for three calves of each group
(Supplementary Material).
In the CON group, M. haemolytica DNA loads increased
regularly over time from inclusion (T0) to the end of the
experiment (T3) in all the three tested calves, from 3.3 to 8.6
log10 DNA copies/mL of BAL, suggesting strong replication of
the bacteria in the lower respiratory tract. At T1, just prior to
early treatment, bacterial DNA loads were similar between the
four groups, at approximately 3 log10 DNA copies/mL of BAL.
Differences were then observed according to treatment. In the
E2 group, marbofloxacin administration at T1 induced a drastic
decrease in the bacterial load until euthanasia. At T2, one of the
three E2 calves was negative, and all E2 calves were negative at
the end of the experiment (T3). In groups L2 and L10, which
were treated 33–35 h later, the bacterial load increased in a similar
manner as the control group until T2 of late treatment. Then,
the bacterial load decreased in both groups, and this decrease
appeared to be higher in the L10 group treated with 10mg/kg
marbofloxacin. At T3 of euthanasia, only one L10 calf exhibited
positive BAL (5.6 log10 DNA copies/mL), whereas all the three
L2 calves were positive, with loads ranging from 3.6 to 3.7 log10
DNA copies/mL.
The mean M. haemolytica DNA loads were significantly
different between the CON group and the E2, L2, L10 groups
at T3, between E2 and L2 at T3, and between E2 and L10 at T2
(Figure 2A). In addition, ABS scores in BAL indicated significant
differences between the CON and the E2 and L2 groups and
between the E2 and L2 groups (Figure 2B).
Distribution and Loads of M. haemolytica
in Respiratory Tissues Showed Differences
between Marbofoxacin Treatments
To further investigate the PCR results, we tested all the 22
included calves for the presence of M. haemolytica in BAL and in
post-mortem tissue samples at T3 of euthanasia (Supplementary
Material). The mean DNA loads in BAL were 7, 0, 2.3, and 1 log10
DNA copies/mL for calves in the CON, E2, L2, and L10 groups,
respectively, with 4 of 4, 0 of 6, 4 of 6, and 1 of 6 positive calves in
each respective group.
In parallel, 4 of 4, 2 of 6, 5 of 6, and 4 of 6 calves in the
CON, E2, L2, and L10 groups, respectively, were positive for M.
haemolytica in at least one of the 5 respiratory tissues (right and
left cranial lobes, accessory and cardiac lobes, tracheobronchial
lymphatic node) tested in each calf. Large differences were
observed when considering the number of positive samples per
calf and per group. In the E2 group, only the intermediate lobe of
one calf and the left cranial lobe of another calf were positive,
with moderate titers of 3.8 and 3.9 log10 DNA copies/100mg
(Figure 3). In contrast, 80% of the tissue samples of the CON
group were positive, whereas the L2 and L10 groups similarly
had 37% of tissue samples as positive. In the CON group, high
DNA individual titers, ranging between 4.6 and 8.2 log10 DNA
copies/100 mg, were detected in positive samples (Figure 3).
The situation was intermediate in the L2 and L10 groups, with
mean loads ranging from 0.7 to 3.2 log10 DNA copies/100 mg,
depending on the type of tissue. The meanM. haemolytica DNA
loads in each tissue samples (Figure 3) also indicated significant
differences between the CON and E2 group, despite large intra-
group variability. To confirm the results obtained by qPCR
in tissue samples, a direct bacterial culture and titration was
performed on the right cranial lobe of the lungs (Table 1). In
the E2 group, all samples collected for bacterial culture remained
negative, even the two samples that were slightly positive with
PCR. For the CON, L2, and L10 groups, the M. haemolytica
counts globally mimicked those obtained by PCR, except for two
calves in the L2 group for which culture was slightly positive but
not with PCR analysis (Table 1).
Treatment with Marbofloxacin Induce
Clinical Improvement within 24h
To determine whether bacterial growth was associated with
change of clinical status, we assessed calves for clinical signs
and lesions over time. All calves were healthy prior to and
immediately after inoculation. At this time, the mean rectal
temperature was 38.8 ± 0.4◦C. Twenty-two of thirty-two calves
were selected based on rectal temperature elevation. These calves
were randomly allocated into one of four groups just after
receiving the respective treatment.
Rectal temperature of the included calves peaked between 3
and 9 h after challenge.Mean rectal temperature peaked at 40.2◦C
at the time of inclusion in all groups. Then, rectal temperature
decreased over time in all groups. Rectal temperature decreased
to baseline within 6 h after early treatment in E2 group and
within 12 h after late treatment in the L2 and L10 groups. In
the non-treated animals, rectal temperature remained above the
temperature of the treated groups at each time point, indicating
a significant difference between E2 calves and non-treated calves
at T2 (data not shown).
Clinical signs started at 6 ± 3 h and peaked between
24 and 40 h after inoculation for most calves. After peak,
clinical signs of CON calves slightly decreased throughout
the course of infection. In the other groups, clinical signs
were very similar to those observed in the CON group until
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FIGURE 2 | Mean titers (qPCR, Roche Light Cycler 480, standard 2nd derivative method) of M. haemolytica DNA copies (with standard deviations) in
bronchoalveolar lavages (A) and mean accumulated bacterial shed (B) in calves treated with 2mg/kg (E2) marbofloxacin at 4 h after inclusion or
2mg/kg (L2) or 10mg/kg (L10) marbofloxacin at 36h after inclusion. The black and red arrows indicate the time of early and late treatments respectively.
Significant differences: *p < 0.05; **p < 0.01; ***p < 0.001.
FIGURE 3 | Mean titers (qPCR, Roche Light Cycler 480, standard 2nd derivative method) of M. haemolytica DNA copies (with standard deviations) in
respiratory post-mortem tissues of calves not treated (), treated with 2mg/kg marbofloxacin at 4 h after inclusion (E2, ), or 2mg/kg (L2, ), or
10mg/kg (L10, ) marbofloxacin at 36h after inclusion. Significant differences are shown in the table: *p < 0.05; **p < 0.01.
each treatment. Consequently, for clinical score evaluation, all
calves were considered as a unique group until marbofloxacin
administration, as shown in Figure 4A. To summarize, the
clinical signs were moderate in most of calves and severe in
two CON calves over time and one L2 calf and one L10
calf prior to treatment. In the CON group, one of the two
calves with severe disease was euthanized at 56 h after infection
for ethical reasons. Moderate signs included hyperthermia,
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tachypnea and dyspnea with labored breathing. In severe forms,
reduced appetite, depression, recumbence, and severe dyspnea
with labored breathing and abnormal lung sounds (wheezes and
crackles) were observed.
The mean clinical scores indicated that marbofloxacin
injections were followed by a rapid (within 24 h) clinical
improvement of calves, regardless of early or late treatment
(Figure 4A). Twenty-four hours after each respective treatment,
4 of 6 E2 and L2 calves and all of the L10 calves presented
a clinical score less than 4 (Table 1). Forty-eight hours after
treatment up to the end of the experiment, clinical scores
remained <4 for all calves in the treated groups. Significant
differences were observed between the non-treated animals and
the E2 group at 24 h, between the CON group and E2, L2, and
L10 groups at 48 and 72 h after infection, and finally between
the CON group and the E2 and L10 groups at 96 h post infection
(Figure 4A).
The accumulated clinical score (ACS) was evaluated for each
calf of each group from the time of infection until the time of
euthanasia (T3). The mean ACS for each group indicated strong
differences between the treated and non-treated groups, with
significant differences only between the E2 and CON groups
(Figure 4B).
Early Treatment with the Low-Dose
Prevent Pulmonary Lesions
Lung lesions were primarily observed in all calves in the CON
group. Lung damage was observed in the cranial lobes and was
typical of acute infection with M. haemolytica, including a high
tissue consolidation and a dark-red to gray-red lobular coloration
with foci of necrosis. Lung lesions were also frequently associated
with pleuresia and fibrin deposits. The mean percentage of
cranioventral lung consolidation was 38, 5, 11, and 1% in
the CON, E2, L2, and L10 groups, respectively. However, the
extension of the gross lesions varied greatly between animals.
In the CON group, two calves exhibited severe lesions on both
cranial and caudal lobes, one calf exhibited lesions on cranial
lobes only, and one calf presented only very restricted lesions. In
all groups, calves with the most severe lung lesions also presented
the highest individual clinical score and high M. haemolytica
content in the lungs (Table 1).
At histopathology, 75, 16.7, 66.7, and 50% of CON, E2, L2, and
L10 calves, respectively, had microscopic lesions in at least one
lobe of the lung. Considering the extension of the microscopic
lesions, 46.9, 4.2, 22.9, and 12.5% of the lobes were positive in the
CON, E2, L2, and L10 groups, respectively.
In the CON group, microscopic lesions were located in all
lung lobes for two of four calves and only in cranial lobes of the
two other animals. By comparison with normal lung microscopic
examination (Figure 5A), lesions were specific to an acute
severe bronchopneumonia and characterized by an hemorrhagic
alveolitis with large fibrinous deposits and major infiltration
of leucocytes (Figure 5B), foci of necrosis surrounded by oat
cells and altered neutrophils (Figure 5C), interlobular edema and
thrombosis (Figure 5C), moderate quantities of mucus in the
lumen of bronchioles and leucofibrinous pleuresia (score of 2).
This type of lesion (score of 2) was not observed for E2 calves
but was observed to a small extent in three of the six calves in
the L2 and L10 groups. In addition, histopathological lesions of
sub-acute bronchopneumonia (score of 1) were also observed but
with less frequency in only one calf in each of the four included
groups. In this case, lesions were characterized by a fibrinous
and macrophagic alveolitis associated with small abscesses or
pyogranulomas of the lung parenchyma (Figure 5D).
The mean histopathological score for each group is shown
in Figure 5E, with strong but no significant differences between
the treated and not treated calves, except between the E2
and CON groups. This mean score was correlated with the
total cranioventral percentage of lobe consolidation (Figure 5F),
except for one E2 calf that exhibited a low histopathological score,
despite moderate consolidation.
DISCUSSION
The objective of this study was to assess the efficacy of a decreased
marbofloxacin regimen when administered at early-time of
infection, on bacterial burden and clinical outcomes in calves
infected with M. haemolytica. To fulfill this objective, we first
developed an experimentalmodel for the detection and treatment
of M. haemolytica mimicking field conditions. BRD treatments
are frequently administered after visual appraisal of clinical
respiratory signs. However, because these signs often occur
late in the disease course (Schaefer et al., 2007), hyperthermia
is increasingly frequently used to promptly detect and treat
BRD in young cattle. In a French field study conducted in
young bulls, Timsit et al. (2011) demonstrated that episodes of
hyperthermia (>39.7◦C) preceded the onset of nasal discharge,
abnormal lung sounds, and depression by a mean of 19,
38.8, and 51.2 h, respectively. To be consistent with these field
observations, we delayed early and late treatments by 30 h.
Moreover, we included calves for early treatments based on
an increase in rectal temperature of 1◦C compared to their
basal rectal temperature. This 1◦C implementation matches with
the temperature threshold commonly used for treatment and
previously reported as an early sign of BRD (Galyean et al.,
1995; Schaefer et al., 2007; Timsit et al., 2011). At the same time,
a challenge dose of 4 × 107 CFU/calf was used to mimic the
clinical signs of a natural infection. First, in a previous pilot
study, we tested two doses: 1010 and 107 CFU/calf using the
same model of infection (data not shown). The high inoculum
lead to a severe superacute disease inducing death in the first
24 h, as observed in other experimental models using bacterial
load infused in lungs over 109 CFU (Fajt et al., 2004; Burciaga-
Robles et al., 2010; Hanzlicek et al., 2010; Rose-Dye et al., 2011).
In contrast, the 107 CFU dose was associated with a moderate to
severe disease evolving in 4–5 days and allowed longer clinical
and bacteriological monitoring at the infectious site. Secondly,
the qPCR threshold (Ct) values of non-treated calves of these
two studies ranged between 19–32 and 19.9–35 in the BAL T2 or
T3 and the lung tissues, respectively. These values fit with those
obtained (Ct range of 24–36) by the same method for the field
BRD diagnostic during a winter season (personal data from 105
samples with 24 samples positive for M. haemolytica). Finally
the choice of the two doses of marbofloxacin was based on a
PK/PD evaluation of antimicrobial efficacy previously published
for M. haemolytica (Valle et al., 2012; Potter et al., 2013). The
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FIGURE 4 | Mean clinical scores (A) and mean accumulated clinical scores (B) of calves inoculated with M. haemolytica and treated with 2mg/kg (E2)
marbofloxacin at 4 h after inclusion (black arrow) or 2mg/kg (L2) or 10mg/kg (L10) marbofloxacin at 36h after inclusion (red arrow). For (A), calves
remained in the control group until the time of treatment. For (B), individual ACS were determined as the area under the curve of clinical scores collected at −16, 6,
24, 40, 72, and 96 h (Graph Pad software, La Jolla, USA). Significant differences: *p < 0.05; **p < 0.01; ***p < 0.001.
FIGURE 5 | Microscopic examination. (A) Normal lung microscopic examination (hemalun and eosin, x200). (B) Lesions of hemorrhagic alveolitis, large fibrinous
deposits, and major infiltration of leucocytes, score of 2 (hemalun and eosin, ×200). (C) oat cells and altered neutrophils, score of 2 (hemalun and eosin, ×200). (D)
Macrophagic alveolitis, score of 1 (hemalun and eosin, ×200). (E) Mean histopathological score (+/− sd) of calves challenged with M. haemolytica and treated with 2
or 10mg/kg marbofloxacin at the early or late stages of infection. (F) Correlation between the total cranioventral percentage of lobe consolidation (gross lesions, ×
axis) and number of lobes with microscopic lesions (y-axis).
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high dose of 10mg/kg matched with the current recommended
dose of marbofloxacin, as mentioned in the commercial product
(FORCYL R©) with the indication for treatment of BRD. The low
dose was the lowest dose ensuring bactericidal efficacy in vitro on
a targeted low inoculum ofM. haemolytica (Lhermie et al., 2015).
To our knowledge, this is the first study assessing the
kinetics of M. haemolytica loads in the lower respiratory tract
of calves for more than 5 consecutive days. Our results in the
control group (Figure 2) indicated a continuous increase in
bacterial loads in the BAL from the start to the end of the
experiment, confirming our model of infection. Unfortunately
it was not possible to strengthen our PCR results by bacterial
load counts for practical reasons. Nevertheless, these assessments
were performed using a commercialized qPCR kit that is highly
repeatable and reproducible and that is increasingly used to
diagnose M. haemolytica in the field (Pelletier, 2013). PCR or
qPCR methods were also shown to detect significantly higher
number of positive cases than culture for M. haemolytica or
H. somni (Tegtmeier et al., 2000; Angen et al., 2009; Bell
et al., 2014) and much faster (Guenther et al., 2008). To our
knowledge, only another study assessed M. haemolytica growth
during the 48 h after infection with a similar inoculum load (108
CFU/calf). The authors observed an increased bacterial count
in bronchial secretions until 18 h post-infection, with a plateau
of 107 CFU/mL until the end of the experiment (Sarasola et al.,
2002). Differences of bacteria kinetics between the two studies
may be due to the method of quantification because part of the
DNA for PCR titration may have been obtained from bacteria
killed by the immune response of calves. Another possibility is
virulence difference of the M. haemolytica A1 strain used in this
study, which was previously confirmed to be highly replicative
and pathogenic in calves.
Our model of M. haemolytica infection showed that a single
early treatment with a single dose of 2mg/kg marbofloxacin led
to the rapid elimination of bacteria in all infected calves between
30 and 116 h after injection. All E2 calves were negative for
M. haemolytica detection in BAL at the end of the experiment.
Only 2 out of 30 tissues samples contained low DNA quantities
(<4 log10 copies/100mg). The rapid clearance ofM. haemolytica
after early treatment with a lower marbofloxacin dose than that
currently recommended (10mg/kg) might be explained by the
relatively low loads of bacteria observed in BALs at T1, suggesting
that the required regimen to obtain bacterial elimination is
dependent (partly or mostly) on the size of the inoculum at
the time of treatment. These results are supported by those
obtained in various in vitro and in vivo studies conducted with
fluoroquinolones, stressing the influence of bacterial cell density
on the efficacy of these antibiotics (Mizunaga et al., 2005; Ferran
et al., 2007; Kesteman et al., 2009; Udekwu et al., 2009).Moreover,
in a recent experimental study testing bactericidal efficacy of
marbofloxacin in a mouse-lung infection model using either M.
haemolytica or P. multocida strains with close marbofloxacin
MICs, we observed that the administration of a lower dose
of marbofloxacin (given 10 h after inoculation) led to total
eradication of a bacterial load of 108 CFU/lung ofM. haemolytica.
In contrast, a similar dose completely failed to achieve bacterial
elimination of a bacterial load of 108 CFU/lung of P. multocida
(Lhermie et al., 2015). These results indicated that marbofloxacin
was much more efficacious against M. haemolytica than P.
multocida, in a mouse model which is not a natural host of
these pulmonary pathogens. In the natural host model tested in
the present study, which is particularly sensitive to the virulence
factors expressed by M. haemolytica such as leukotoxin (Van
Donkersgoed et al., 1993; Apley, 1997; Zecchinon et al., 2005),
we confirmed the ability of an early marbofloxacin treatment to
produce rapid and complete microbiological cure.
Compared with the early treatment, calves treated 30 h later
with the same 2mg/kg dose of antibiotic displayed a different
pattern. Significant differences in DNA titers were found between
the E2 and L2 groups in BALs at T3 and in accumulated
bacterial loads. Large differences in M. haemolytica DNA titers,
although not significant, were also observed between the two
groups considering both the number of calves with positive
lung samples and the total number of positive tissues per calf.
The situation appears to be slightly different when calves were
treated later but with a high 10mg/kg dose of marbofloxacin.
No significant differences were observed between the E2 and L10
groups at T3 of euthanasia. In the L10 group, M. haemolytica
was detected in 10 of 30 respiratory samples but in only 2 of
6 tested calves. Further, even if bacterial loads were similar in
the L2 and L10 calves just prior to treatment (T2), only one L10
calf presented moderate bacteria DNA titers in BAL 3 days after
treatment (T3), whereas all the three L2 calves remained positive,
suggesting that an increased marbofloxacin dosage from 2 to
10mg/kg was associated with higher bacterial elimination when
treatments area initiated later. This result is also supported by
the decrease in mean DNA titers shown in Figure 2, suggesting
that clearance of bacteria was faster for the L10 than L2
group and was likely similar between the L10 and E2 groups.
These results are in agreement with previous works, confirming
that fluoroquinolones display a concentration-dependent killing
mechanism of M. haemolytica (Sarasola et al., 2002; Illambas
et al., 2013). Finally, our results simultaneously confirm the
concentration-dependent behavior of fluoroquinolones against
Gram-negative bacteria for a given bacterial load, and suggests
that the size of the bacterial load at the time of treatment
influences the range of exposure magnitude required to obtain
bacterial eradication.
Taken together, these results from an experimental model
highlight the benefits of using early treatments with a low dose
of antibiotic that should lead to a fast cure of M. haemolytica
infection in the lower respiratory tract. One major question for
livestock professionals is the impact of such early treatment
on animal health and also human health by limiting antibiotic
consumption. In this study, we only focused on animal health
by assessing clinical signs and lesions of infected and treated
calves. In the control group, rectal temperature and mean clinical
score peaked within 3–12 and 24–40 h following challenge,
respectively, reached a plateau, and then slightly decreased until
the end of the experiment. This mimics the precedence of
hyperthermia as observed in field conditions and supported
in numerous respiratory challenge models (Fajt et al., 2004;
Burciaga-Robles et al., 2010; Hanzlicek et al., 2010; Forbes et al.,
2011; Rose-Dye et al., 2011; Crouch et al., 2012). In our challenge
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model reproducing moderate to severe disease, early or late
treatments with marbofloxacin clearly induced recovery of all
calves in <24 h. These results are supported by those obtained
in field studies that have monitored the effects of marbofloxacin
on rectal temperature and clinical status of animals naturally
infected with various respiratory pathogens (Thomas et al., 2001;
Grandemange et al., 2012). Total ACS showed major differences
between the control and E2, L2, and L10 groups; however, these
differences were only significant between the E2 and control
groups (Figure 4B). Themain explanationsmay be the variability
of individual response in the challenge model or more likely,
the delay of treatment, as clinical scores decreased similarly
in all treated groups within 24 h after antibiotic injection,
with significant differences compared with the control group
(Figure 4A).
Our results also suggest that early treatment may prevent
pulmonary lesions.Whatever the antibiotic dosage, treatment led
to a low frequency of lung lesions, but significant differences for
histopathological scores were only observed between the E2 and
control groups. Further, calves treated earlier presented a lower
percentage of cranioventral lung consolidation, a lower number
of lobes with macroscopic and microscopic lesions, and lower
histopathological scores compared with calves treated 30 h later.
Again, these results could be associated with rapid elimination
of bacterial burden, avoiding bacterial growth and thus the onset
of pulmonary damage. We also observed that lesion severity was
correlated with bacterial load in the lungs. Our results agree
with those reported in another experimental BRD model, in
which a positive relationship between the severity of clinical
signs, cumulative clinical scores, and extension of pulmonary
macroscopic and microscopic lesions was observed (Forbes et al.,
2011).
However, it is unclear why, despite increasing high qPCR
titers in the lungs, we did not observe severe disease with
extensive pulmonary lesions in some of the non-treated animals.
This observation suggests that implementation of on-field
therapy based on early diagnosis of illness and using decreased
antimicrobial regimen may require specific diagnosis tools to
measure bacterial load and/or, if possible, a precise monitoring
of markers correlated with early infection stage.
Promoting a dose modulated concurrently with the infectious
bacterial load could be difficult to implement in cattle production
under actual field conditions. Indeed, quantification of bacterial
content in respiratory samples is not currently performed,
although the present qPCR is now used in several veterinary
laboratories (Pelletier, 2013). The main caveat is the minimum
1 day-time to obtain a quantitative result, which implies that
the treatment would delivered with a delay, when bacterial loads
would be already higher than when initially tested. However,
constantly more rapid and easier techniques are being developed
for detection and quantification of bacteria such as LAMP-
PCR, biosensors, reflectance spectroscopy, raman spectroscopy
etc....(for review Noble and Weisberg, 2005; Velusamy et al.,
2010). Since our model and another study (Sarasola et al., 2002)
showed a correlation between the bacterial content and the
apparition and evolution of the disease, on-field strategy based
on early diagnosis of illness (with efficient markers) and using
decreased antimicrobial regimen could be considered in field
conditions. We recently performed a field study to evaluate
antimicrobial consumption and therapeutic efficacy of an early
vs. late treatment protocol with a similar decreased antimicrobial
regimen (marbofloxacin 2 or 10mg/kg) in 195 young bulls with
BRD. Our results suggest that the combination of an early
detection of disease (increase of body core temperature) with a
decreased marbofoxacin treatment reduces drug consumption at
the herd level without affecting treatment efficacy compared to
a standard therapy. (Lhermie et al., submitted). Such findings
evidence the possible rationalization of antimicrobial use under
field conditions, to limit impact on public health.
To conclude, to our knowledge, this is the first time that a
decreased antimicrobial regimen administered at early time of
infection and targeting a low bacterial load demonstrated efficacy
in a bovine natural host experimental model. The responses
to the treatments, in terms of bacterial elimination, pulmonary
lesions, and clinical recovery, were similar between the lower
dose (low inoculum-adjusted) administered at an early time of
infection and the higher dose (high inoculum-adjusted) given
at a later time of infection. Altogether, our results are proof of
principle that there is a place for the optimization of antibiotic
doses in food-producing animals, provided strict conditions
of early diagnosis of illness and/or bacterial load that allow
combining the cure of bacterial infections with the reduction of
antibiotic consumption. Regarding antimicrobial consumption
under public health considerations, further studies evaluating the
benefits of modulating dose regimens have to be encouraged.
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